UNLOCKING & PSYCHEDELIC THERAPEUTICS INNOVATIVE CANNABINOID A world leading synthetic biology platform company enabling the development of effective cannabinoid and psychedelic therapeutics BIOLOGY THE POWER OF

WORLD LEADING SYNTHETIC BIOLOGY PLATFORM

Octarine is perfecting a biological approach​
to producing natural, novel, and improved cannabinoid and psychedelic molecules with tailored modes-of-action. ​

Our proprietary technology utilizes synthetic biology, yeast fermentation and enzymatic derivatization to develop IP protected drug candidates validated in pre-clinical models.

CHANGES ARE NEEDED

MANY NEUROLOGICAL AND PSYCHOLOGICAL CONDITIONS ARE POORLY SERVED BY CURRENT DRUGS

A significant number of patients don’t respond to any available treatment ultimately leaving patients and their families desperately seeking alternatives

33

Neurological disorders affect >12% globally. ~33% of epilepsy patients are drug resistant.

40

Anorexia affects > 3.8% globally. ~40% don’t respond to any available treatments.

37

Mental disorders affect >13% globally. ~30% of patients with Major Depressive Disorder are treatment resistant5

.

THE WORLD IS READY FOR A NEW TREATMENT PARADIGM

WITH MOLECULES SHOWING EFFICACY RATES FAR HIGHER THAN ANY DRUG CANDIDATE EVER TESTED.

There is now a wealth of robust clinical data showing that cannabinoids and psychedelics are significantly more effective than current first line treatments in a range of disease indications

OCTARINE IS AT THE FOREFRONT OF TECHNOLOGICAL INNOVATION

We are unlocking the potential of nature and harnessing synthetic biology to re-design radical new approaches to combat poorly served health conditions

TO A BIO REVOLUTION OCTARINE IS PAVING THE ROAD FORWARD THE WAY

A BIO REVOLUTION IN THE CANNABINOID AND PSYCHEDELIC INDUSTRIES 

Octarine’s competitive advantage and key differentiator is its use of synthetic biology, a breakthrough technology already disrupting industries ranging from pharmaceuticals to consumer products.

Synthetic biology provides the tools to engineer biological processes to deliver targeted, rapid and sustainable solutions

PROPRIETARY SYNTHETIC BIOLOGY PLATFORMS ACCELERATING THE DRUG DEVELOPMENT PROCESS

Octarine develops highly modular and scalable “biological factories” to sustainably and cost-effectively produce natural and novel drug candidates 

Enzymes are biological machines which have evolved to efficiently catalyse chemical reactions far beyond made-made synthetic chemistry.

Octarine develops high-throughput platforms to discover and engineer enzymes catalyzing valuable chemical reactions allowing us to produce natural molecules as well as novel molecules not seen in nature nor in synthetic chemistry. ​

Ultimately giving us access to unique drug candidates that up until now have been unavailable to drug developers

A “bio-foundry” where enzymatic processes can be combined and rapidly scaled to produce drug candidates.​

Fermentation is a well-established manufacturing method routine in many industries.

While it’s favoured for supply-chain stability and sustainability (utilizing renewable sugar as the bulk input), it additionally offers Octarine two important advantages.​

Scalability: Where a process validated at lab-scale can be rapidly scaled to meet demand within months.​

Modularity: Where a single validated process can produce a range of different derivatives simply by adding different biosynthetic enzymes

Demonstrating the potential of bio-based drug candidates with a core focus on conditions with quantitative pre-clinical and clinical biomarkers.

De-risking the drug development process by avoiding conditions characterized by qualitative and subjective biomarkers which make it particularly difficult to assess and compare the clinical efficacy of new drug candidates

OB-CAN GLY: OCTARINE’S PROPRIETARY 2ND GENERATION CANNABINOID DERIVATIVES

Produced by biocatalysis

While cannabinoids have ground-breaking therapeutic potential, their poor pharmacokinetic properties, in particular their complete insolubility, rapid degradation, and low bioavailability and absorption severely limit their therapeutic application. To overcome these issues Octaine has used enzymatic glycosylation to produce a library of novel cannabinoid glycosides with ideal pharmacokinetic properties. With access to a diverse library of proprietary cannabinoid drug candidates, Octarine is currently exploring the potential of these optimized molecules in pre-clinical studies for a number of indications.

23,000

23,000 fold increase in water solubility

HIGHLY STABLE – No degradation observed under a range of extreme conditions

17 x

17x increase in intestinal absorption - giving Increased oral bioavailability

OBP -001: OCTARINE’S PSILOCYBIN API

Produced by fermentation-based manufacturing

While natural psychedelics such as psilocybin show breakthrough potential to treat a range of psychological and neurological disorders, access to stable, consistent GMP-grade molecules remains a bottleneck. Octarine has developed its own in-house manufacturing process using yeast fermentation enabling a cost-efficient, scalable and most importantly, highly-sustainable method for producing psychedelic drug candidates without the use of petrochemical precursors or other environmentally harmful substances. While this process will initially be used to produce our own psilocybin API for human clinical trials, the modularity of our biosynthetic approach means this single fermentation process will be used to rapidly produce a wide range of natural and novel psychedelic derivatives​.

PSYCHEDELICS 2.0: OCTARINE’S PROPRIETARY LIBRARY OF NOVEL PSYCHEDELIC DERIVATIVE

Produced by our high-throughput biocatalysis and fermentation platforms
While there is a significant need and opportunity to apply safe and well-studied natural psychedelics to treat debilitating disorders, it’s clear that the future of psychedelic medicine lies in novel compounds with improved and optimized properties. And already, a clear picture is emerging on the potential limitations of natural psychedelic molecules. Using our high-throughput biocatalysis platforms, which can produce novel derivatives inaccessible to traditional synthetic chemistry, and our fermentation platform, which rapidly produce these molecules at scale, Octarine is building a library of IP protected 2nd generation molecules to screen for improved therapeutic effect.

  Library designed to identify improved properties including: 

TARGETED SEROTONIN RECEPTOR BINDING​

REDUCED “TRIP” DURATION​

REDUCED/ABSENT HALLUCINOGENIC EFFECT

​​Screened in a proprietary pre-clinical model to quantify for the first-time, the therapeutic effect of psychedelics

BIOLOGY, BIOCHEMISTRY READ MORE ABOUT THE TEAM AND DRUG DISCOVERY EXPERTS IN SYNTHETIC TEAM THE INTERNATIONAL

GROUNDBREAKING RESEARCH PERFORMED IN OUR STATE-OF-THE-ART LABORATORY

Fully licensed by the Danish government to import, export, manufacture and conduct research with all controlled drugs and substances

Our purpose-built lab in the center of Copenhagen Denmark is fully equipped to perform R&D in synthetic biology, enzymology, biochemistry, and drug-discovery. Octarine’s R&D team are experts in their field with the majority at PhD level and with peer-reviewed scientific publications in the worlds most prestigious journals  

REACHING THE GOALS – DEVELOPMENT TIMELINE

Follow us here Twitter Want to learn more?
You can reach out to us here
info@octarinebio.com Linkedin